JPH10139687A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPH10139687A JPH10139687A JP29256996A JP29256996A JPH10139687A JP H10139687 A JPH10139687 A JP H10139687A JP 29256996 A JP29256996 A JP 29256996A JP 29256996 A JP29256996 A JP 29256996A JP H10139687 A JPH10139687 A JP H10139687A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- alcohol
- present
- urea
- external
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims abstract description 22
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims abstract description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004202 carbamide Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000005690 diesters Chemical class 0.000 claims abstract description 12
- 239000003906 humectant Substances 0.000 claims abstract description 12
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000001387 anti-histamine Effects 0.000 claims abstract description 11
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 11
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 11
- 235000011037 adipic acid Nutrition 0.000 claims abstract description 10
- 239000001361 adipic acid Substances 0.000 claims abstract description 10
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 11
- -1 carbon atoms Diester Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 6
- 229960004194 lidocaine Drugs 0.000 claims description 6
- 229960000520 diphenhydramine Drugs 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 22
- 230000037336 dry skin Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 208000003251 Pruritus Diseases 0.000 abstract description 11
- 210000003491 skin Anatomy 0.000 description 32
- 235000019441 ethanol Nutrition 0.000 description 17
- 239000000523 sample Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 230000001139 anti-pruritic effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002649 leather substitute Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940100613 topical solution Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 101710200374 Crotamine Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(57)【要約】
【課題】 乾燥性皮膚とそう痒との両方に効き目を示し
且つ適用によるべとつき感を改善された皮膚外用液剤を
提供する。
【解決手段】 尿素8〜23w/v%、抗ヒスタミン剤
0.3〜 4w/v%、局所麻酔剤0.5〜5w/v%、低級
アルコール40〜70w/v%、保湿剤0.1〜30w/v%
及び炭素数4以下のアルコールとアジピン酸及び/又は
セバシン酸とから構成されるジエステル0.5〜20w/
v%と精製水とを必須成分として含有することを特徴と
するべとつき感の改善された皮膚外用液剤。PROBLEM TO BE SOLVED: To provide a skin external solution which has an effect on both dry skin and pruritus and has an improved sticky feeling by application. SOLUTION: Urea 8-23 w / v%, antihistamine 0.3-4 w / v%, local anesthetic 0.5-5 w / v%, lower alcohol 40-70 w / v%, humectant 0.1-30 w / v%
And a diester composed of an alcohol having 4 or less carbon atoms and adipic acid and / or sebacic acid 0.5 to 20 w /
An external preparation for skin with improved tackiness, comprising v% and purified water as essential components.
Description
【0001】[0001]
【発明の属する技術分野】本発明はべとつき感の改善さ
れた皮膚外用液剤、詳しくは乾燥性皮膚治療作用及び鎮
痒作用を合せ持ち且つべとつき感の改善された新しい皮
膚外用液剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin external preparation having an improved tackiness, and more particularly to a new skin external preparation having a dry skin treatment and an antipruritic effect and having an improved stickiness.
【0002】[0002]
【従来の技術】最近医療福祉の現場において、乾燥性皮
膚疾患の問題が大きく取り沙汰されるようになってきて
おり、該乾燥性皮膚疾患は、アトピー性皮膚炎、老人性
乾皮症等に代表されるように、皮膚が乾燥、角化するだ
けでなく、常にそう痒を伴う疾患である。特に老人性乾
皮症につき詳述すれば、高齢者の皮膚は加齢に伴う皮膚
の萎縮と共に皮脂分泌量、皮膚血流量が減少し、また角
層水分量が少なくなることにより、乾燥、角化しやすく
なり、それらに伴って、湿疹、かゆみ等が生じ、掻破に
より全身に亘る皮膚炎となることもあり、とりわけ寝た
きり老人にとっては、かゆみが不眠やいらいら、食欲不
振等の二次的障害をもたらすともいわれ、高齢化社会へ
と向かっている現在、上記問題はもはや一部の人のもの
とはいえなくなっている。2. Description of the Related Art In recent years, the problem of dry skin disease has been widely raised in the field of medical and welfare. The dry skin disease is typified by atopic dermatitis, senile xerosis, etc. As it is, not only is the skin dry and keratinized, but also a condition that is always itchy. In particular, the senile xeroderma is described in detail.Skin of the elderly decreases in sebum secretion and cutaneous blood flow with the atrophy of the skin with aging. Eczema, itch, etc. occur along with them, and dermatitis may occur throughout the body due to scratching. It is said that the above problems will no longer apply to some people as they are moving toward an aging society.
【0003】また近年環境及び衣食住のスタイルの急激
な変化によりアレルギー患者が増えつつあり、それに伴
いアレルギーの引き起こすアトピー性皮膚炎の患者も急
増している。之等の患者は皮膚の乾燥や荒れによる外見
上の問題と激しいかゆみによる不快感、更に精神的な不
安や苦痛に悩まされている。In recent years, the number of allergic patients has been increasing due to rapid changes in the environment and the style of eating, eating, and living. Along with this, the number of patients with atopic dermatitis causing allergy has also increased rapidly. These patients are suffering from cosmetic problems due to dry and rough skin, discomfort due to severe itching, and mental anxiety and pain.
【0004】乾燥性皮膚疾患は、上述した病因のために
その治癒が困難であり、更に悪いことにはかゆみにより
掻破痕や血痂を生じ、病態が悪化する傾向もある。従っ
てその治療には、皮膚の乾燥だけでなくかゆみも抑える
ことができる薬剤が必要となる。[0004] Dry skin diseases are difficult to cure due to the above-mentioned etiology, and even worse, itching tends to produce scratches and blood crusts, and the pathology tends to worsen. Therefore, for the treatment, an agent capable of suppressing not only itching but also itching of the skin is required.
【0005】しかるに現在、乾燥性皮膚疾患に対して用
いられている市販の多くの皮膚外用剤は、いずれも上記
乾燥性皮膚疾患の治療に満足できる性能を具備するもの
ではない。即ち、市販の皮膚外用剤は、乾燥性皮膚又は
そう痒のどちらか一方にしか作用を示さず、一剤で両方
を治療できるものは存在しない。従って、市販品を乾燥
性皮膚疾患の治療に用いる場合は、二剤を併用しなけれ
ばならず、患者にとって極めて不便である。また市販の
皮膚外用剤は殆どの場合、剤型が軟膏剤かクリーム剤で
あり、之等は使用者にとり、べたつき感等の不快感を伴
い、また使用部に埃等の異物が付着しやすくなる問題が
あり、乾燥性皮膚疾患に対しては好ましいものではな
い。[0005] However, none of the many commercially available skin external preparations currently used for dry skin diseases have satisfactory performance in the treatment of the above-mentioned dry skin diseases. That is, a commercially available skin external preparation only shows an effect on either dry skin or pruritus, and there is no one that can treat both with one agent. Therefore, when a commercial product is used for the treatment of dry skin disease, two agents must be used in combination, which is extremely inconvenient for patients. In addition, most of the commercially available skin external preparations are in the form of ointments or creams, which cause discomfort such as stickiness to the user, and foreign substances such as dust easily adhere to the used area. However, it is not preferable for dry skin diseases.
【0006】一方、病院内処方として、クロタミン製剤
やコルチコステロイド製剤に有効量の尿素を配合したも
のが知られている〔皮膚疾患と外用製剤(南山堂)参
照〕が、之等は上記市販品を単に混合したものに過ぎ
ず、剤型も必然的に軟膏剤かクリーム剤に限定され、不
快感や異物付着の問題を解消され得ない。[0006] On the other hand, as a prescription in a hospital, a crotamine preparation or a corticosteroid preparation containing an effective amount of urea is known [see Skin Diseases and Topical Preparations (Nanzando)]. It is merely a mixture of products, and the dosage form is necessarily limited to ointments or creams, and the problems of discomfort and adhesion of foreign substances cannot be solved.
【0007】以上のように、従来の皮膚外用剤はこれを
乾燥性皮膚疾患に適用するには問題があり、この問題を
解決した外用剤、即ち乾燥性皮膚とそう痒との両方に効
き目を示し且つ使用感が良好で異物付着の問題のない新
しい外用剤が斯界で要望されていた。[0007] As described above, the conventional external preparation for skin has a problem in applying it to dry skin diseases. The external preparation which solved this problem, that is, has an effect on both dry skin and pruritus. There has been a need in the art for a new external preparation which exhibits good feeling in use and has no problem of adhesion of foreign substances.
【0008】本発明者らは、上記斯界の要望に合致する
外用液剤として、所定量の尿素、抗ヒスタミン剤、局所
麻酔剤、低級アルコール及び保湿剤からなる皮膚外用液
剤を先に提供するに成功した〔特開平3−291221
号公報参照〕。The present inventors have previously succeeded in providing a skin external solution comprising a predetermined amount of urea, an antihistamine, a local anesthetic, a lower alcohol and a moisturizer as an external solution which meets the above-mentioned demands in the art [ JP-A-3-291221
Reference).
【0009】この皮膚外用液剤は、従来のこの種液剤に
比して使用感等のかなりの改善が認められしかも所期の
乾燥性皮膚とそう痒との両方に効き目を示すものであっ
たが、尚、その適用によるべとつき感(主に保湿効果を
奏する保湿剤及び尿素による)の点で、改善される余地
を残していた。This external preparation for skin shows a considerable improvement in the feeling of use, etc., as compared with the conventional liquid preparation of this kind, and shows an effect on both the intended dry skin and pruritus. However, there is room for improvement in the sticky feeling (mainly due to the humectant and urea having a moisturizing effect) due to the application.
【0010】[0010]
【発明が解決しようとする課題】従って、本発明の目的
は、従来の外用剤に見られる問題点を解消され、特に乾
燥性皮膚疾患患者への適用に適し、しかもその適用によ
るべとつき感の点でも満足できる改善の認められる新し
い外用剤を提供することにある。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to solve the problems found in conventional external preparations, and in particular, it is suitable for application to patients with dry skin diseases and has a sticky feeling due to the application. However, it is an object of the present invention to provide a new external preparation which can be satisfactorily improved.
【0011】本発明者らは、上記目的より、殊に尿素、
抗ヒスタミン剤、局所麻酔剤、低級アルコール及び保湿
剤を含む外用液剤につき、鋭意研究を重ねた結果、上記
外用液剤に更に炭素数4以下のアルコールとアジピン酸
及び/又はセバシン酸とから構成されるジエステルの所
定量を配合するときには、該ジエステルが特にべとつき
感の改善に優れた効果を奏し、かくして、乾燥性皮膚治
療作用、鎮痒作用、保湿作用等を有し、しかもべとつき
感の顕著に改善された、上記目的に合致する液剤形態の
外用剤が得られることを見出だし、ここに本発明を完成
するに至った。[0011] The present inventors have found that, in particular, urea,
As a result of intensive studies on a topical solution containing an antihistamine, a local anesthetic, a lower alcohol and a humectant, the above-mentioned topical solution further contains a diester composed of an alcohol having 4 or less carbon atoms and adipic acid and / or sebacic acid. When the prescribed amount is blended, the diester has a particularly excellent effect of improving the sticky feeling, and thus has a dry skin treatment effect, an antipruritic effect, a moisturizing effect, etc., and the sticky feeling is remarkably improved. It has been found that an external preparation in a liquid form meeting the above object can be obtained, and the present invention has been completed.
【0012】[0012]
【課題を解決するための手段】本発明によれば、下記組
成範囲の各成分と精製水とを必須成分として含有するこ
とを特徴とするべとつき感の改善された皮膚外用液剤が
提供される。According to the present invention, there is provided a skin external preparation having an improved sticky feeling, characterized by containing each of the following composition ranges and purified water as essential components.
【0013】 尿素 8 〜23w/v% 抗ヒスタミン剤 0.3〜 4w/v% 局所麻酔剤 0.5〜 5w/v% 低級アルコール 40 〜70w/v% 保湿剤 0.1〜30w/v% 炭素数4以下のアルコールとアジピン酸及び/又はセバ
シン酸とから構成されるジエステル 0.
5〜20w/v%。Urea 8-23 w / v% Antihistamine 0.3-4 w / v% Local anesthetic 0.5-5 w / v% Lower alcohol 40-70 w / v% Humectant 0.1-30 w / v% Carbon number Diester composed of 4 or less alcohol and adipic acid and / or sebacic acid
5-20% w / v.
【0014】また、本発明によれば、抗ヒスタミン剤が
ジフェンヒドラミンであり、局所麻酔剤がリドカインで
あり且つ低級アルコールがエタノール及び/又はイソプ
ロピルアルコールである上記皮膚外用液剤、及び炭素数
4以下のアルコールとアジピン酸及び/又はセバシン酸
とから構成されるジエステルをべとつき感改善剤とする
尿素含有皮膚外用液剤が提供される。Further, according to the present invention, the above-mentioned external skin preparation wherein the antihistamine is diphenhydramine, the local anesthetic is lidocaine and the lower alcohol is ethanol and / or isopropyl alcohol, and an alcohol having 4 or less carbon atoms and adipine There is provided a urea-containing external skin solution containing a diester composed of an acid and / or sebacic acid as a sticky feeling improving agent.
【0015】本発明の皮膚外用剤は、上記特定組成を有
する液剤形態としたことに基づき、乾燥性皮膚治療作用
と鎮痒作用とを合せ有し、しかもべとつき感の改善によ
る優れた使用感をも有し、更に異物付着の問題を伴わな
い利点を有している。The external preparation for skin of the present invention, which is in the form of a liquid preparation having the above-mentioned specific composition, has both a dry skin treatment effect and an antipruritic effect, and also has an excellent feeling of use due to an improved sticky feeling. In addition, it has the advantage of not causing the problem of foreign matter adhesion.
【0016】また本発明皮膚外用剤は、尿素の分解及び
それにより生成するアンモニアの量が少ない点でも、よ
り安定である利点をも有している。The external preparation for skin of the present invention also has the advantage of being more stable in that the decomposition of urea and the amount of ammonia produced thereby are small.
【0017】[0017]
【発明の実施の形態】本発明液剤において、尿素は乾燥
性皮膚治療の薬効成分として用いられるものであり、そ
の配合量は上記薬効を示すのに充分な量、即ち全組成物
の8〜23%(w/v%、以下同じ)、好ましくは10〜
20%の範囲から選択されるのが重要であり、この範囲
を外れる量、特に上記範囲を下回る量で用いる場合、本
発明所期の効果は奏し得なくなる。DESCRIPTION OF THE PREFERRED EMBODIMENTS In the liquid preparation of the present invention, urea is used as a medicinal ingredient for dry skin treatment, and its compounding amount is an amount sufficient to exhibit the above medicinal effect, that is, 8 to 23 of the total composition. % (W / v%, the same applies hereinafter), preferably 10
It is important to select from the range of 20%, and when used in an amount outside this range, particularly in an amount below the above range, the intended effect of the present invention cannot be achieved.
【0018】また、本発明液剤は抗ヒスタミン剤及び局
所麻酔剤のそれぞれ所定量を含有することが重要であ
る。之等はいずれも鎮痒成分として働くものであり、該
抗ヒスタミン剤としては、代表的にはジフェンヒドラミ
ン、その塩酸塩、タンニン酸塩等の薬理的に許容される
塩等を、また局所麻酔剤としては、代表的にはリドカイ
ンを、それぞれ有利に利用できる。之等の配合量は、抗
ヒスタミン剤としてのジフェンヒドラミンの場合、0.
3〜4%、好ましくは0.5〜2%の範囲、また局所麻
酔剤としてのリドカインの場合、0.5〜5%、好まし
くは1〜3%の範囲とするのがよく、之等配合量範囲に
おいて、本発明所期の効果を奏し得る。It is important that the liquid preparation of the present invention contains predetermined amounts of an antihistamine and a local anesthetic. These act as antipruritic components, and as the antihistamine, typically, pharmacologically acceptable salts such as diphenhydramine, its hydrochloride, tannate, etc., and as a local anesthetic, Typically, lidocaine can each be used to advantage. In the case of diphenhydramine as an antihistamine, the amount of these components is 0.1.
In the range of 3-4%, preferably 0.5-2%, and in the case of lidocaine as a local anesthetic, the range is 0.5-5%, preferably 1-3%. Within the amount range, the desired effect of the present invention can be achieved.
【0019】本発明の皮膚外用液剤には、上記各必須薬
効成分の他に、之等各成分の薬効を補うために、他の同
様の薬効成分を付加的に添加配合することもできる。上
記他の薬効成分としては、乾燥性皮膚治療成分として例
えばサリチル酸等を、鎮痒成分として例えばクロタミト
ン、マレイン酸クロルフェニラミン等を例示できる。但
し之等の配合量は本発明製剤が液剤形態を保持する量と
する必要がある。In addition to the above-mentioned essential medicinal components, other similar medicinal components may be additionally added to the liquid preparation for external use of the present invention in order to supplement the medicinal effects of these components. Examples of the other medicinal components include salicylic acid and the like as dry skin treatment components, and crotamiton and chlorpheniramine maleate as antipruritic components. However, the amount of these components must be such that the preparation of the present invention maintains the liquid form.
【0020】本発明液剤は、更に保湿剤を必須成分とし
て含有しており、これは尿素の保湿及び乾燥性皮膚治療
作用を助長する働きがある。該保湿剤としては、従来公
知の各種のもののいずれでもよく、その具体例としては
例えばグリセリン、プロピレングリコール、1,3−ブ
チレングリコール等の多価アルコール類、ポリエチレン
グリコール、ヒドロキシプロピルセルロース等の水溶性
高分子物質、その他乳酸、乳酸ナトリウム等を例示でき
る。之等保湿剤の本発明液剤中への配合割合は、該保湿
剤の種類により若干異なるが、0.1〜30%の範囲か
ら適宜選択されるのがよく、薬効成分の作用や製剤の妨
げとならない量とするのはいうまでもない。The liquid preparation of the present invention further contains a humectant as an essential component, which has the function of promoting the action of urea for moisturizing and treating dry skin. As the humectant, any of various conventionally known humectants may be used, and specific examples thereof include polyhydric alcohols such as glycerin, propylene glycol and 1,3-butylene glycol, and water-soluble polymers such as polyethylene glycol and hydroxypropyl cellulose. Examples thereof include polymeric substances, lactic acid, and sodium lactate. The mixing ratio of the humectant in the liquid preparation of the present invention is slightly different depending on the type of the humectant, but may be appropriately selected from the range of 0.1 to 30%. It is needless to say that the amount is not so large.
【0021】更に、本発明液剤は基剤として低級アルコ
ールを40〜70%用いることを特徴とする。該低級ア
ルコールとしては、特にエタノール及び/又はイソプロ
パノールが好ましい。該エタノールは前記した本発明に
必須の各成分の溶解力に優れ、また水ともよく混和する
ので、薬剤及び水分を皮膚から吸収し易くする作用があ
ると共に、殺菌消毒作用をも有し、更に使用後は皮膚か
ら速やかに蒸発するので、軟膏剤やクリーム剤のような
べとつき感を与えず、加えて蒸発熱を奪うことで皮膚に
清涼感をもたらす利点がある。Further, the liquid preparation of the present invention is characterized in that a lower alcohol is used in an amount of 40 to 70% as a base. As the lower alcohol, ethanol and / or isopropanol are particularly preferable. The ethanol is excellent in the dissolving power of each of the essential components of the present invention and is well miscible with water, so that it has an action of facilitating the absorption of drugs and water from the skin, and also has a disinfecting action. Since it evaporates quickly from the skin after use, it does not give a sticky feeling like an ointment or cream, and has an advantage that it gives a refreshing feeling to the skin by removing heat of evaporation.
【0022】また本発明液剤には、その必須成分とし
て、アジピン酸及び(又は)セバシン酸のジエステルを
0.5〜20w/v%、好ましくは2〜12w/v%含有させ
ることが重要であり、この配合によって、角層水分保持
効果を有する尿素が主たる原因となって生じるべたつき
感の改善を図ることができる。上記ジエステルを構成す
るアルコール成分としては、炭素数4以下のもの、例え
ばメチルアルコール、エチルアルコール、n−プロピル
アルコール、イソプロピルアルコール、n−ブチルアル
コール、t−ブチルアルコール等を例示できる。It is important that the liquid preparation of the present invention contains, as an essential component, a diester of adipic acid and / or sebacic acid in an amount of 0.5 to 20 w / v%, preferably 2 to 12 w / v%. With this composition, it is possible to improve the sticky feeling which is mainly caused by urea having a horny layer moisture retaining effect. Examples of the alcohol component constituting the diester include those having 4 or less carbon atoms, such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, and t-butyl alcohol.
【0023】本発明の皮膚外用液剤は、上記各成分を含
有する限り、その製法は特に限定されるものではない
が、一般には前記必須薬効成分を混合して、アジピン酸
及び/又はセバシン酸のジエステル、低級アルコール及
び水の一部に溶解させた後、該溶液に保湿剤を添加し、
これに残余の水を追加して均一な液剤形態とすることに
より調製される。The method for preparing the external preparation for skin of the present invention is not particularly limited as long as it contains each of the above-mentioned components. Generally, the essential medicinal components are mixed to form a mixture of adipic acid and / or sebacic acid. After dissolving in a part of diester, lower alcohol and water, a humectant is added to the solution,
It is prepared by adding the remaining water to this to make a uniform liquid form.
【0024】また本発明液剤には、上記各成分以外に、
必要に応じて他の薬効成分等、例えばカンフル、グリチ
ルレチン酸、サリチル酸メチル等の消炎剤、メントー
ル、ハッカ油等の清涼剤、ユーカリ油等の香料、トコフ
ェロール等のビタミン類、消臭剤、安定化剤等を適宜添
加配合することも可能である。In addition to the above-mentioned components, the liquid preparation of the present invention further comprises
If necessary, other medicinal ingredients and the like, for example, anti-inflammatory agents such as camphor, glycyrrhetinic acid, methyl salicylate, etc., cooling agents such as menthol, peppermint oil, fragrances such as eucalyptus oil, vitamins such as tocopherol, deodorants, stabilization It is also possible to appropriately add and mix agents and the like.
【0025】かくして調製される本発明の皮膚外用液剤
は、これを適当な容器に充填して製品とされ、これは、
一回にその適当量を患部に滴下又は塗布具等により塗布
することにより適用される。また、スプレー容器に充填
して噴霧方式により適用可能な製品形態とすることも可
能である。The thus-prepared solution for external use on the skin of the present invention is filled into a suitable container to obtain a product, which comprises:
It is applied by dropping or applying an appropriate amount to the affected area at a time by using an applicator or the like. Further, it is also possible to fill a spray container into a product form applicable by a spray method.
【0026】本発明の皮膚外用液剤は、一剤で乾燥性皮
膚治療とそう痒治療効果とを奏することができ、特に乾
燥性皮膚疾患の治療に好適であるに加えて、べたつき感
が殆どなく、使用感が非常に良好であり、また潤滑作用
を有しており、更にその適用時に異物付着等の問題もほ
とんど起らない利点がある。The liquid preparation for external use on the skin of the present invention can exert a dry skin treatment and a pruritus treatment effect by a single agent. In addition to being suitable for the treatment of dry skin diseases, it has almost no sticky feeling. It has the advantage that it has a very good feeling in use, has a lubricating effect, and hardly causes problems such as adhesion of foreign substances when applied.
【0027】[0027]
【実施例】以下、本発明を更に詳しく説明するため、本
発明皮膚外用液剤の製造例を実施例として挙げ、次いで
本発明液剤の有効性を明らかにする臨床試験例及び性能
試験例を挙げる。EXAMPLES Hereinafter, in order to explain the present invention in more detail, a production example of a liquid preparation for external use on the skin of the present invention will be described as an example, followed by a clinical test example and a performance test example for clarifying the effectiveness of the liquid preparation of the present invention.
【0028】[0028]
【実施例1】 尿素 10g ジフェンヒドラミン塩酸塩 1g リドカイン 2g エタノール 45g 1,3−ブチレングリコール 20g セバシン酸ジエチル 4g精 製 水 適 量 全 量 100ml 上記量の尿素、ジフェンヒドラミン塩酸塩及びリドカイ
ンの混合物に、エタノール及び約10gの精製水を加え
て撹拌溶解させた。更に得られた溶液に上記量の1,3
−ブチレングリコール及びセバシン酸ジエチルを加えた
後、残余の精製水を追加して全量を100mlとして、
本発明皮膚外用液剤を調製した。Example 1 Urea 10 g Diphenhydramine hydrochloride 1 g Lidocaine 2 g Ethanol 45 g 1,3-butylene glycol 20 g Diethyl sebacate 4 g Refined water qty 100 ml About 10 g of purified water was added and dissolved by stirring. Further, the above solution was added to the solution obtained in the above amount.
-After adding butylene glycol and diethyl sebacate, add the remaining purified water to make the total volume 100 ml,
A skin preparation for external use of the present invention was prepared.
【0029】[0029]
【実施例2】 尿素 10g ジフェンヒドラミン塩酸塩 1g リドカイン 2g カンフル 1g 酢酸トコフェロール 0.3g エタノール 48g 1,3−ブチレングリコール 10g 乳酸ナトリウム 5g アジピン酸ジイソプロピル 5g精 製 水 適 量 全 量 100ml 上記各成分の所定量を用いて、実施例1と同様にして、
本発明皮膚外用液剤を調製した。Example 2 Urea 10 g Diphenhydramine hydrochloride 1 g Lidocaine 2 g Camphor 1 g Tocopherol acetate 0.3 g Ethanol 48 g 1,3-butylene glycol 10 g Sodium lactate 5 g Diisopropyl adipate 5 g Refined water qs 100 ml And in the same manner as in Example 1,
A skin preparation for external use of the present invention was prepared.
【0030】[0030]
【実施例3〜6】下記表1に示す各成分の所定量を用い
て、実施例1と同様にして、本発明皮膚外用液剤を調製
した。Examples 3 to 6 In the same manner as in Example 1 except that predetermined amounts of the respective components shown in Table 1 below were used, liquid preparations for external use on the skin of the present invention were prepared.
【0031】[0031]
【表1】 [Table 1]
【0032】[0032]
【試験例1】 (1)供試薬剤実施例3〜5で得た本発明皮膚外用液剤
(それぞれ本発明試料1〜3とする)及び比較のためセ
バシン酸ジエチルを含まない以外は実施例3と同様にし
て調製した液剤(比較試料とする)を用いた。Test Example 1 (1) Reagents Example 3 was applied except that the liquid for external use of the skin of the present invention (samples 1 to 3 of the present invention) obtained in Examples 3 to 5 and diethyl sebacate were not used for comparison. A liquid preparation (comparative sample) prepared in the same manner as described above was used.
【0033】(2)被験者 男性7名(20〜40歳)及び女性7名(20〜30
歳)の計14名を選んだ。(2) Subjects 7 males (20 to 40 years old) and 7 females (20 to 30 years old)
A total of 14 people were selected.
【0034】(3)試験方法 被験者の両前腕屈側部のそれぞれ2カ所を被検部位とし
て、本発明試料1〜3及び比較試料の各供試薬剤を各部
位に順次塗布し、それらのべとつき感を対比して官能評
価した。該評価は、快(100)、許容(0)及び不快
(−100)の直線を引いたべとつき度判定記録紙上に
マークされた各試料A及びBの数値により判定した。ま
た、上記数値より、各供試試料について、そのべとつき
感の許容性を下記式に従って算出した。(3) Test method Using two test sites on both sides of each subject's forearm flexure, test reagents of the present invention samples 1 to 3 and a comparative sample were sequentially applied to each site, and their tackiness was applied. The sensory evaluation was made by comparing the feeling. The evaluation was made based on the numerical values of the samples A and B marked on the sticky degree judgment recording paper by drawing straight lines of pleasant (100), acceptable (0) and unpleasant (-100). From the above numerical values, the acceptability of the tackiness of each test sample was calculated according to the following equation.
【0035】べとつき感の許容性(%)=〔1−(許容
未満と評価した(−評価)被験者数)/14〕×100 (4)結果 得られた結果を下記表2及び図1〔実施例4で得た本発
明試料2(図中、線(1)として示す)と比較試料(図
中、線(2)として示す)との対比データ〕に示す。Acceptability of stickiness (%) = [1− (number of subjects evaluated as less than allowable (−evaluation)) / 14] × 100 (4) Results The results obtained are shown in Table 2 below and FIG. Comparative data between the sample 2 of the present invention (shown as a line (1) in the figure) obtained in Example 4 and a comparative sample (shown as a line (2) in the figure)].
【0036】[0036]
【表2】 [Table 2]
【0037】上記図1及び表2より、アジピン酸ジエス
テル及びセバシン酸ジエステルのそれぞれを配合した本
発明皮膚外用液剤試料1〜3は、これを配合しない比較
試料に比して、いずれもべとつき感が顕著に軽減されて
いるとの評価を得、このことから、上記ジエステルの添
加配合は、液剤の塗布後のべとつき感の改善効果を奏す
ることが明らかである。From FIG. 1 and Table 2, it can be seen that each of the skin external liquid samples 1 to 3 of the present invention containing each of adipic acid diester and sebacic acid diester had a sticky feeling as compared with the comparative sample not containing this. It was evaluated that it was remarkably reduced, and it is clear from this that the addition and blending of the diester has an effect of improving the tackiness after application of the liquid preparation.
【0038】[0038]
【試験例2】 (1)供試薬剤 本発明試料2及び3及び比較試料を用いた。Test Example 2 (1) Reagents Samples 2 and 3 of the present invention and a comparative sample were used.
【0039】(2)被験者 男性3名(20〜40歳)及び女性2名(20〜30
歳)の計5名を選んだ。(2) Subjects 3 males (20-40 years old) and 2 females (20-30 years old)
5) in total.
【0040】(3)試験方法 被験者の左前腕屈側部の2カ所及び右腕屈側部の1カ所
を被検部位(各4cm×4cm)として、各被検部位に
各試料のそれぞれ20μlを均一に塗布し、経時的に角
層水分量を測定した。測定は、高周波電導度測定装置
(浜松IBM社製、内極2mm、外極4〜6mmの高感
度プローブ装着)を用いて、塗布前、塗布直後、塗布3
0分後、塗布60分後及び塗布120分後にそれぞれ3
回ずつ実施し、その平均値を測定値とした。(3) Test Method Two portions on the left forearm flexion side and one on the right arm flexion side of the subject were set as test sites (4 cm × 4 cm each), and 20 μl of each sample was uniformly applied to each test site. And the water content of the stratum corneum was measured over time. The measurement was carried out using a high-frequency conductivity measuring device (manufactured by Hamamatsu IBM Co., Ltd., with a high-sensitivity probe with an inner pole of 2 mm and an outer pole of 4 to 6 mm) before, immediately after, and
3 minutes after 0 minute, 60 minutes after application and 120 minutes after application
The measurement was performed each time, and the average value was used as the measured value.
【0041】同一被験者につき、測定日を替えて同一試
験を再度実施し、延べ10名についてデータを得た。The same test was repeated for the same subject, changing the measurement date, and data was obtained for a total of 10 subjects.
【0042】(4)結果 得られたデータを下記表3に示す。(4) Results The data obtained are shown in Table 3 below.
【0043】[0043]
【表3】 [Table 3]
【0044】表3より、本発明試料は、アジピン酸ジエ
ステル及びセバシン酸ジエステルの添加配合によって
も、実質的に尿素による保湿作用に悪影響を与えられて
いないことが判る。From Table 3, it can be seen that the sample of the present invention has substantially no adverse effect on the moisturizing effect of urea even by the addition and mixing of adipic acid diester and sebacic acid diester.
【0045】[0045]
【試験例3】 (1)供試薬剤 実施例6で得た本発明皮膚外用液剤試料及び比較試料1
を用いた。Test Example 3 (1) Reagents The liquid sample for external use of the skin of the present invention obtained in Example 6 and the comparative sample 1
Was used.
【0046】(2)試験方法 各製剤試料0.1mlを人工皮革上に塗布し、その上を
一定の荷重をかけた摩擦子(シリコン製)を水平に移動
させて、人工皮革と摩擦子に生じるMIU(平均摩擦係
数)を、塗布直後、塗布30分、60分及び120分後
の4点において測定した。(2) Test Method 0.1 ml of each preparation sample was applied on artificial leather, and a friction element (made of silicon) with a constant load was moved horizontally on the artificial leather to apply the artificial leather and the friction element. The resulting MIU (mean coefficient of friction) was measured at four points immediately after, 30 minutes, 60 minutes and 120 minutes after application.
【0047】(3)測定条件 次の条件を採用した。(3) Measurement conditions The following conditions were adopted.
【0048】力の感度 〔H(力計20g/V)〕 移動スピード〔1mm/sec〕 摩擦静荷重〔25g〕 摩擦センサー〔シリコンセンサー〕 (4)測定結果 結果を下記表4に示す。Force sensitivity [H (dynamometer 20 g / V)] Moving speed [1 mm / sec] Static friction load [25 g] Friction sensor [silicon sensor] (4) Measurement results The results are shown in Table 4 below.
【0049】[0049]
【表4】 [Table 4]
【0050】摩擦テスターにおけるMIUの値は、人間
が物体の表面をこするときに感じる滑りやすさ・滑りに
くさとの相関がとられている。上記MIUの値が大きく
なるほど、官能評価において滑りにくいと評価される。The MIU value of the friction tester is correlated with the slipperiness and the difficulty of slipping when a person rubs the surface of an object. As the value of the MIU increases, it is evaluated that the MIU is less slippery in the sensory evaluation.
【0051】上記表3より、本試験において、セバシン
酸ジエステルを添加配合した本発明皮膚外用液剤試料
は、セバシン酸ジエステルを添加配合しなかった比較試
料に比して、MIUの値が低くなっており、このことか
ら上記ジエステルの添加は得られる液剤に優れた潤滑作
用を与えることが明らかとなった。As shown in Table 3, in this test, the MIU value of the skin external preparation sample of the present invention to which sebacic acid diester was added was lower than that of the comparative sample to which sebacic acid diester was not added. From this, it was clarified that the addition of the diester had an excellent lubricating effect on the resulting liquid.
第1図は薬理試験例1に従い求められた本発明皮膚外用
液剤のべとつき感を評価したグラフである。FIG. 1 is a graph showing the evaluation of the sticky feeling of the liquid preparation for external use on the skin of the present invention obtained in accordance with Pharmacological Test Example 1.
Claims (4)
成分として含有することを特徴とするべとつき感の改善
された皮膚外用液剤。 尿素 8 〜23w/v% 抗ヒスタミン剤 0.3〜 4w/v% 局所麻酔剤 0.5〜 5w/v% 低級アルコール 40 〜70w/v% 保湿剤 0.1〜30w/v% 炭素数4以下のアルコールとアジピン酸及び/又はセバ
シン酸とから構成されるジエステル 0.
5〜20w/v%1. A liquid preparation for external use with improved sticky feeling, comprising the following components in the following composition ranges and purified water as essential components: Urea 8-23 w / v% Antihistamine 0.3-4 w / v% Local anesthetic 0.5-5 w / v% Lower alcohol 40-70 w / v% Humectant 0.1-30 w / v% C4 or less 1. Diester composed of alcohol and adipic acid and / or sebacic acid
5-20 w / v%
成分として含有することを特徴とするべとつき感の改善
された皮膚外用液剤。 尿素 10 〜20w/v% 抗ヒスタミン剤 0.5〜 2w/v% 局所麻酔剤 1 〜 3w/v% 低級アルコール 40 〜70w/v% 保湿剤 0.1〜30w/v% 炭素数4以下のアルコールとアジピン酸及び/又はセバ
シン酸とから構成されるジエステル 2
〜12w/v%2. A liquid preparation for external use on the skin having an improved sticky feeling, comprising the following components in the following composition ranges and purified water as essential components. Urea 10-20 w / v% Antihistamine 0.5-2 w / v% Local anesthetic 1-3 w / v% Lower alcohol 40-70 w / v% Humectant 0.1-30 w / v% Alcohol having 4 or less carbon atoms Diester composed of adipic acid and / or sebacic acid 2
~ 12w / v%
あり、局所麻酔剤がリドカインであり且つ低級アルコー
ルがエタノール及び/又はイソプロピルアルコールであ
る請求項1に記載の皮膚外用液剤。3. The liquid preparation according to claim 1, wherein the antihistamine is diphenhydramine, the local anesthetic is lidocaine, and the lower alcohol is ethanol and / or isopropyl alcohol.
及び/又はセバシン酸とから構成されるジエステルをべ
とつき感改善剤とする尿素含有皮膚外用液剤。4. A urea-containing external skin solution containing a diester composed of an alcohol having 4 or less carbon atoms and adipic acid and / or sebacic acid as a sticky feeling-improving agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29256996A JPH10139687A (en) | 1996-11-05 | 1996-11-05 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29256996A JPH10139687A (en) | 1996-11-05 | 1996-11-05 | External preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10139687A true JPH10139687A (en) | 1998-05-26 |
Family
ID=17783476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29256996A Pending JPH10139687A (en) | 1996-11-05 | 1996-11-05 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10139687A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002167328A (en) * | 2000-11-29 | 2002-06-11 | Toyo Aerosol Ind Co Ltd | Composition and aerosol composition for external skin preparation |
JP2005314331A (en) * | 2004-04-30 | 2005-11-10 | Junichi Yamashita | Ointment |
JP2021134182A (en) * | 2020-02-28 | 2021-09-13 | 国立大学法人山口大学 | Surface anesthetic |
-
1996
- 1996-11-05 JP JP29256996A patent/JPH10139687A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002167328A (en) * | 2000-11-29 | 2002-06-11 | Toyo Aerosol Ind Co Ltd | Composition and aerosol composition for external skin preparation |
JP2005314331A (en) * | 2004-04-30 | 2005-11-10 | Junichi Yamashita | Ointment |
JP2021134182A (en) * | 2020-02-28 | 2021-09-13 | 国立大学法人山口大学 | Surface anesthetic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4230109B2 (en) | Pharmaceutical composition comprising an amphoteric surfactant, an alkoxylated cetyl alcohol and a polar drug | |
KR0143916B1 (en) | Methods for reducing skin irritation associated with drug / penetrant enhancer compositions | |
Flynn | Cutaneous and transdermal delivery—processes and systems of delivery | |
JP3487633B2 (en) | Skin disease treatment emulsion | |
Purdon et al. | Foam drug delivery in dermatology: Beyond the scalp | |
JPH05178764A (en) | Application of dibutyl adipate and isopropyl myristate in locally applied or percutaneously absorptive product | |
JPH11502513A (en) | Methods for treating diabetic neuropathy | |
JPH03291221A (en) | Liquid for external use on the skin | |
HU226065B1 (en) | Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases | |
JP3504279B2 (en) | Skin atrophy relieving agent and its use | |
JPH09255565A (en) | Hydrogel patch for dermal local anesthesia | |
Ainley-Walker et al. | Side to side comparison of topical treatment in atopic dermatitis | |
JPH0338524A (en) | Corticosteroid-containing lotions | |
JPH09110680A (en) | Dermatitis-curing strap | |
JPH10139687A (en) | External preparation for skin | |
JP2007262030A (en) | Topical skin preparation | |
JP3798927B2 (en) | Blood circulation promoting topical skin preparation | |
JPH11246329A (en) | Skin preparation for external use | |
US8367683B2 (en) | Composition and method for treatment of warts | |
JP3723728B2 (en) | Skin topical solution | |
JP3560072B2 (en) | External base | |
JP2000198718A5 (en) | ||
JP3827259B2 (en) | Keratinization promoter | |
JP2001278768A (en) | Skin care preparation | |
JPH0692290B2 (en) | Skin cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Effective date: 20031217 Free format text: JAPANESE INTERMEDIATE CODE: A02 |